Anthracycline cardiotoxicity

From bench to bedside

Luca Gianni, Eugene H. Herman, Steven E Lipshultz, Giorgio Minotti, Narine Sarvazyan, Douglas B. Sawyer

Research output: Contribution to journalArticle

303 Citations (Scopus)

Abstract

Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.

Original languageEnglish
Pages (from-to)3777-3784
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number22
DOIs
StatePublished - Sep 22 2008

Fingerprint

Anthracyclines
Combination Drug Therapy
Antineoplastic Agents
Italy
Education
Cardiotoxicity
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008). Anthracycline cardiotoxicity: From bench to bedside. Journal of Clinical Oncology, 26(22), 3777-3784. https://doi.org/10.1200/JCO.2007.14.9401

Anthracycline cardiotoxicity : From bench to bedside. / Gianni, Luca; Herman, Eugene H.; Lipshultz, Steven E; Minotti, Giorgio; Sarvazyan, Narine; Sawyer, Douglas B.

In: Journal of Clinical Oncology, Vol. 26, No. 22, 22.09.2008, p. 3777-3784.

Research output: Contribution to journalArticle

Gianni, L, Herman, EH, Lipshultz, SE, Minotti, G, Sarvazyan, N & Sawyer, DB 2008, 'Anthracycline cardiotoxicity: From bench to bedside', Journal of Clinical Oncology, vol. 26, no. 22, pp. 3777-3784. https://doi.org/10.1200/JCO.2007.14.9401
Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: From bench to bedside. Journal of Clinical Oncology. 2008 Sep 22;26(22):3777-3784. https://doi.org/10.1200/JCO.2007.14.9401
Gianni, Luca ; Herman, Eugene H. ; Lipshultz, Steven E ; Minotti, Giorgio ; Sarvazyan, Narine ; Sawyer, Douglas B. / Anthracycline cardiotoxicity : From bench to bedside. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 22. pp. 3777-3784.
@article{e8973a06725442fc8c314d6b3ad03049,
title = "Anthracycline cardiotoxicity: From bench to bedside",
abstract = "Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.",
author = "Luca Gianni and Herman, {Eugene H.} and Lipshultz, {Steven E} and Giorgio Minotti and Narine Sarvazyan and Sawyer, {Douglas B.}",
year = "2008",
month = "9",
day = "22",
doi = "10.1200/JCO.2007.14.9401",
language = "English",
volume = "26",
pages = "3777--3784",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

TY - JOUR

T1 - Anthracycline cardiotoxicity

T2 - From bench to bedside

AU - Gianni, Luca

AU - Herman, Eugene H.

AU - Lipshultz, Steven E

AU - Minotti, Giorgio

AU - Sarvazyan, Narine

AU - Sawyer, Douglas B.

PY - 2008/9/22

Y1 - 2008/9/22

N2 - Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.

AB - Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.

UR - http://www.scopus.com/inward/record.url?scp=49249135889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49249135889&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.14.9401

DO - 10.1200/JCO.2007.14.9401

M3 - Article

VL - 26

SP - 3777

EP - 3784

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 22

ER -